Pfizer Inc. (NYSE:PFE) Shares Bought by State of Wyoming

State of Wyoming boosted its holdings in Pfizer Inc. (NYSE:PFE) by 293.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,335 shares of the biopharmaceutical company’s stock after purchasing an additional 16,652 shares during the quarter. State of Wyoming’s holdings in Pfizer were worth $593,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. Tallon Kerry Patrick purchased a new stake in Pfizer during the fourth quarter valued at about $509,000. Merit Financial Group LLC grew its position in Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock valued at $3,395,000 after acquiring an additional 48,397 shares during the period. Sax Wealth Advisors LLC grew its position in Pfizer by 17.4% during the fourth quarter. Sax Wealth Advisors LLC now owns 10,995 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 1,630 shares during the period. Lake Street Private Wealth LLC grew its position in Pfizer by 8.3% during the fourth quarter. Lake Street Private Wealth LLC now owns 10,096 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 776 shares during the period. Finally, Ameritas Advisory Services LLC grew its position in Pfizer by 3.6% during the fourth quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company’s stock valued at $2,016,000 after acquiring an additional 2,633 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.0%

Shares of NYSE PFE opened at $22.83 on Monday. The stock’s 50 day moving average price is $23.65 and its two-hundred day moving average price is $25.32. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the prior year, the firm posted $0.82 earnings per share. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.